abrdn Income Credit Strategies ACP Pharma — Partners Capital
Other segment segments
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:PartnersCapital.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — partners capital.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — partners capital?
- abrdn Income Credit Strategies (ACP) reported pharma — partners capital of $161M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — partners capital changed year-over-year?
- abrdn Income Credit Strategies's pharma — partners capital decreased by 25.1% year-over-year, from $215M to $161M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — partners capital?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — partners capital has grown at a -7.8% compound annual growth rate (CAGR), from $1.06B to $764M.
- What does pharma — partners capital mean?
- Represents the equity interest held by partners or parent entities within the pharmaceutical segment. This metric indicates the net investment value attributable to the primary stakeholders after accounting for all liabilities. It is essential for understanding the ownership structure and equity base of the business unit.